Curcumin is the main biologically active phytochemical compound of turmeric that has been widely used by ancient cultures throughout Asia. However the dissolution rate limited absorption and pre-absorption degradation limits its use as a potential therapeutic. In this study an attempt has been made to overcome the above limitations by curcumin delivery through nanotechnology. Nanocurcumin solid dosage formulations were prepared and studied for its dissolution behaviour. Considerable improvement in the dissolution behavior was observed in the drug nanocrystal-loaded solid dosage forms. This is expected to enhance the bioavailability of poorly soluble medicinal herbs such as turmeric in the body.
H. Hatcher, R. Planalp, J. Cho, F. M. Torti and S. V. Torti, “Curcumin: From Ancient Medicine to Current Clinical Trials,” Cellular and Molecular Life Sciences, Vol. 65, No. 11, 2008, pp. 1631-1652.
B. Joe, M. Vijaykumar and B. R. Lokesh, “Biological Properties of Curcumin-Cellular and Molecular Mecha nisms of Action,” Critical Reviews in Food Science and Nutrition, Vol. 44, No. 2, 2004, pp. 97-111.
R. K. Maheshwari, A. K. Singh, J. Gaddipati and R. C. Srimal, “Multiple Biological Activities of Curcumin: A Short Review,” Life Sciences, Vol. 78, No. 18, 2006, pp. 2081-2087. doi:10.1016/j.lfs.2005.12.007
A. Duvoix, R. Blasius, S. Delhalle, M. Schnekenburger, F. Morceau, E. Henry, M. Dicato and M. Diederich, “Che mopreventive and Therapeutic Effects of Curcumin,” Cancer Letters, Vol. 223, No. 2, 2005, pp. 181-190.
C. D. Lao, M. T. T. Ruffin, D. Normolle, D. D. Heath, S. I. Murray, J. M. Bailey, M. E. Boggs, J. Crowell, C. L. Rock and D. E. Brenner, “Dose Escalation of a Curcumi noid Formulation,” BMC Complementary and Alternative Medicine, Vol. 6, No. 1, 2006, p. 10.
G. Shoba, D. Joy, T. Joseph, M. Majeed, R. Rajendran and P. S. Srinivas, “Influence of Piperine on the Pharma cokinetics of Curcumin in Animals and Human Volun teers,” Planta Medica, Vol. 64, No. 4, 1998, pp. 353-356.
L. Li, F. S. Braiteh and R. Kurzrock, “Liposome-Encap sulated Curcumin: In Vitro and in Vivo Effects on Prolif eration, Apoptosis, Signaling, and Angiogenesis,” Cancer, Vol. 104, No. 6, 2005, pp. 1322-1331.
Bisht, Savita, et al., “Polymeric Nanoparticle-Encapsulated Curcumin (‘Cur-NC’): A Novel Strategy for Human Cancer Therapy,” Journal of Nanobiotechnology, Vol. 5, No. 3, 2007, p. 3. doi:10.1186/1477-3155-5-3
A. Liu, H. Lou, L. Zhao and P. Fan, “Validated LC/MS/ MS Assay for Curcumin and Tetrahydrocurcumin in Rat Plasma and Application to Pharmacokinetic Study of Phospholipids Complex of Curcumin,” Journal of Phar maceutical and Biomedical Analysis, Vol. 40, No. 3, 2006, pp. 720-727. doi:10.1016/j.jpba.2005.09.032
S. L. Thomas, D. Zhong, W. Zhou, S. Malik, D. Liotta, J. P. Snyder, E. Hamel, and P. Giannakakou, “EF24, a Novel Curcumin Analog, Disrupts the Microtubule Cytoskeleton and Inhibits HIF-1,” Cell Cycle, Vol. 7, No. 15, 2008, pp. 2409-2417.
H. Hatcher, R. Planalp, J. Cho, F. M. Torti and S. V. Torti, “Curcumin: From Ancient Medicine to Current Clinical Trials,” Journal Cellular and Molecular Life Sciences, Vol. 65, No. 11, 2008, pp. 1631-1652.
X. Chen, T. J. Young, M. Sarkari, R. O. Williams and K. P. Johnston, “Preparation of Cyclosporine a Nanoparticles by Evaporative Precipitation into Aqueous Solution,” International Journal of Pharmaceutics, Vol. 242, No. 1, 2002, pp. 3-14. doi:10.1016/S0378-5173(02)00147-3
R. H. Muller, C. Jacobs and O. Kayser, “Nanosuspensions as Particulate Drug Formulations in Therapy Ra tionale for Development and What We Can Expect for the Future,” Advanced Drug Delivery Reviews, Vol. 47, No. 1, 2001, pp. 3-19. doi:10.1016/S0169-409X(00)00118-6
R. H. Muller and C. Jacobs, “Buparvaquone Mucoadhe sive Nanosuspensions: Preparation, Optimisation and Long Term Stability,” International Journal of Pharmaceutics, Vol. 237, No. 1, 2002, pp. 151-161.
C. M. Keck and R. H. Muller, “Drug Nanocrystals of Poorly Soluble Drugs Produced by High Pressure Ho mogenization,” European Journal of Pharmaceutics and Biopharmaceutics, Vol. 62, No. 1, 2006, pp. 3-16.
G. G. Liversidge and K. C. Cundy, “Particle Size Reduc tion for Improvement of Oral Bioavailability of Hydro phobic Drugs: I. Absolute Oral Bioavailability of Nano crystalline Danazol in Beagle Dogs,” International Journal of Pharmaceutics, Vol. 125, No. 1, 1995, pp. 91-97.
J. Jinno, K. Naoki, M. Miyake, K. Yamada, T. Mukia, M. Odomi, H. Togu-chi, G. G. Liversidge, K. Higaki and T. Kimura, “Effect of Particle Size Reduction on Dissolution and Oral Absorption of a Poorly Water-Soluble Drug, Cilostazol, in Beagle Dogs,” Journal of Controlled Re lease, Vol. 111, No. 1-2, 2006, pp. 56-64.
G. G. Liversidge and P. Conzentino, “Drug Particle Size Reduction for Decreasing Gastric Irritancy and Enhancing Absorption of Naproxen in Rats,” International Journal of Pharmaceutics, Vol. 125, No. 2, 1995, pp. 309-313.
L. Gao, D. Zhang and M. Chen, “Drug Nanocrystals for the Formulation of Poorly Soluble Drugs and Its Applica tion as a Potential Drug Delivery System,” Journal of Nanoparticle Research, Vol. 10, No. 5, 2008, pp. 845-862.
R. Ravichandran, “Preparation and Characterisation of Cur cumin Nanosuspension for Enhanced Solubility and Dis solution Velocity,” International Journal of Nano and Bio materials, Vol. 3, No. 2, 2010, pp. 153-186.
F. Dons, Y. Wang, J. Li and Q. Huang, “Preparation of Curcumin Sub-Micrometer Dispersions by High-Pressure Homogenization,” Journal of Agricultural and Food Chemistry, Vol. 58, No. 5, 2010, pp. 2848-2853.
R. H. Muller, C. Jacobs and O. Kayser, “Nanosuspensions for the Formulation of Poorly Soluble Drugs,” In: F. Nielloud and G. Marti-Mestres, Eds., Pharmaceutical Emulsions and Suspensions, Marcel Dekker, New York, 2000, pp. 383-407.
R. H. Muller and A. Akkar, “Drug Nanocrystals of Poorly Soluble Drugs,” In: H. S. Nalwa, Ed., Encyclopedia of Nanoscience and Nanotechnology, American Scientific Publishers, Stevenson Ranch, 2004, pp. 627-638.
R. Takano, K. Furumoto, K. Shiraki, N. Takata, Y. Hayashi, Y. Aso and S. Yamashita, “Rate-Limiting Steps of Oral Absorption for Poorly Water-Soluble Drugs in Dogs; Prediction from a Mini Scale Dissolution Test and a Physiologically-Based Computer Simulation,” Pharma ceutical Research, Vol. 25, No. 10, 2008, pp. 2334-2344.
R. J. Hintz and K. C. Johnson, “The Effect of Particle Size Distribution on Dissolution Rate and Oral Absorp tion,” International Journal of Pharmaceutics, Vol. 51, No. 1, 1989, pp. 9-17.
C. Keck, A. Fichtinger, H. Viernstein and R. H. Muller, “Oral Drug Nanocrystals-Effect of Potential Aggregation on Bioavailability,” Annual Meeting of Pharmaceutical Scientists (AAPS), Baltimore, 2004, p. 2746.